Parasympathetic dysfunction as a risk factor in myocardial infarction: what is the treatment?
Nóbrega
A C
AC
Teixeira De Castro
R R
RR
D000818:Animals; D001342:Autonomic Nervous System Diseases / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D016757:Death, Sudden, Cardiac / Q000209:etiology / Q000517:prevention & control; D004562:Electrocardiography; D006339:Heart Rate / Q000502:physiology; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology; D010275:Parasympathetic Nervous System / Q000503:physiopathology*; D011379:Prognosis; D011729:Pyridostigmine Bromide / Q000627:therapeutic use; D051381:Rats; D015996:Survival Rate
D002800:Cholinesterase Inhibitors; D011729:Pyridostigmine Bromide